3 reports

  • 8.6. NAPABUCASIN / BB-608 (BOSTON BIOMEDICAL) 8.6.1. PRODUCT DESCRIPTION
  • 6.2.3. POPULAR INDICATIONS ON TWITTER

INTRODUCTION Cancer stem cells (CSCs) are known to be rare, immortal cells within a tumor that can both self-renew and differentiate into several cell types that form the tumor mass. Over time, the development of CSCs has been shown to be associated with several signaling pathways, which regulate the survival and proliferation...

  • Cancer
  • Pharmaceutical
  • Therapy
  • Boston Biomedical, Inc.
  • Novartis AG
  • 4.3. CLINICAL PIPELINE
  • CLINICAL PIPELINE

NATURE REVIEWS CANCER EMERGED AS ONE OF THE MOST POPULAR JOURNALS.

  • Cancer
  • Pathology
  • Therapy
  • Demand
  • Boston Biomedical, Inc.
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H1 2018
  • Toll Like Receptor 8 (CD288 or TLR8) - Therapeutics Development

In this trial, ## patients with PASI scores of ##. ## or greater will be randomized ##:##:##:## to receive weekly subcutaneous doses of IMO-## at ##. ##, ##. ##, or ##. ## mg/ kg/ week or placebo for ## weeks.

  • Cancer
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Idera Pharmaceuticals, Inc.